www.fgks.org   »   [go: up one dir, main page]
Jump to content

Plexxikon: Difference between revisions

Edit links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous edit
Content deleted Content added
VisualWikitext
m Correct name
Citation bot (talk | contribs)
Bots
5,010,565 edits
Alter: date, template type. | Use this bot. Report bugs. | Suggested by Spinixster | Category:Pharmaceutical companies of the United States | #UCB_Category 90/220
 
(13 intermediate revisions by 6 users not shown)
Line 1: Line 1:
{{Short description|American drug discovery company}}
{{Infobox company
{{Infobox company
| name = Plexxikon
| name = Plexxikon
| type = Subsidiary
| industry = [[Biotechnology]]
| industry = [[Biotechnology]]
| fate = Acquired by the [[Daiichi Sankyo]]
| fate = Acquired by the [[Daiichi Sankyo]]
| founded = {{Start date and age|2001}}
| founded = {{Start date|2001}}
| founder = [[Joseph Schlessinger]]
| founder = [[Joseph Schlessinger]]
| defunct = {{End date and age|2011}}
| defunct = {{End date and age|2011}}
| hq_location = [[Berkeley]], [[California]], [[United States]].
| hq_location = [[South San Francisco, California|South San Francisco]], [[California]], [[United States]].
}}
}}


'''Plexxikon''' is an American [[drug discovery]] company based in [[Berkeley, California]]. It was co-founded in 2001 by [[Joseph Schlessinger]] of [[Yale University]], and [[Sung-Hou Kim]] of the [[University of California, Berkeley]].
'''Plexxikon''' is an American [[drug discovery]] company based in [[South San Francisco, California]]. It was co-founded in 2001 by [[Joseph Schlessinger]] of [[Yale University]], and [[Sung-Hou Kim]] of the [[University of California, Berkeley]].


It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple technologies, including structural screening as one key component that it hopes will give a significant competitive advantage over other approaches.
It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple technologies, including structural screening as one key component, that it hopes will give a significant competitive advantage over other approaches.{{Citation needed|date=August 2022}}<ref>{{Cite web |title=AI Drug Discovery: Key Trends and Developments in Pharmaceutical Industry |url=https://www.biopharmatrend.com/post/615-pharmaceutical-artificial-intelligence-key-developments-in-2022/ |access-date=2023-09-11 |website=www.biopharmatrend.com |language=en}}</ref>


In April 2011, Plexxikon was acquired by the Japanese pharmaceutical company [[Daiichi Sankyo]] for $805 million and an additional $130 million in potential milestone payments.<ref>{{cite web|title=Daiichi Sankyo to Acquire Plexxikon|url=http://www.plexxikon.com/view.cfm/88/Press-Releases}}</ref><ref>{{Cite web|date=2011-03-03|title=Plexxikon acquired by Daiichi Sankyo|url=https://biopharmconsortium.com/2011/03/03/plexxikon-acquired-by-daiichi-sankyo/|access-date=2020-08-06|website=Haberman Associates|language=en-US}}</ref><ref>{{Cite web|title=Daiichi Sankyo, Inc. Completes Plexxikon Inc. Acquisition|url=https://www.biospace.com/article/daiichi-sankyo-inc-completes-plexxikon-inc-acquisition-/|access-date=2020-08-06|website=BioSpace|language=en-US}}</ref>
In April 2011, Plexxikon was acquired by the Japanese pharmaceutical company [[Daiichi Sankyo]] for $805&nbsp;million and an additional $130&nbsp;million in potential milestone payments.<ref>{{cite web|title=Daiichi Sankyo to Acquire Plexxikon|url=http://www.plexxikon.com/view.cfm/88/Press-Releases |date=2011-02-28 |publisher=Plexxikon |archive-url=https://web.archive.org/web/20110306091816/https://www.plexxikon.com/view.cfm/88/Press-Releases |archive-date=2011-03-06 |url-status=dead}}</ref><ref>{{Cite web|date=2011-03-03|title=Plexxikon acquired by Daiichi Sankyo|url=https://biopharmconsortium.com/2011/03/03/plexxikon-acquired-by-daiichi-sankyo/|access-date=2020-08-06|website=Haberman Associates|language=en-US}}</ref><ref>{{Cite web|title=Daiichi Sankyo, Inc. Completes Plexxikon Inc. Acquisition|url=https://www.biospace.com/article/daiichi-sankyo-inc-completes-plexxikon-inc-acquisition-/|access-date=2020-08-06|website=BioSpace|language=en-US}}</ref>

Daiichi Sankyo announced the shutdown of Plexxikon in 2022.<ref>{{Cite web|first=Madeline |last=Wells|date=2022-01-12|title=South SF company bought for $800 million is being shut down|url=https://www.sfgate.com/local/article/South-SF-Plexxikon-to-shut-down-16770179.php|website=SFGATE|language=en-US |archive-url=https://web.archive.org/web/20220112185128/https://www.sfgate.com/local/article/South-SF-Plexxikon-to-shut-down-16770179.php |archive-date=2022-01-12 |url-status=live}}</ref>


==Drug pipeline==
==Drug pipeline==
*[[Vemurafenib]] (Zelboraf) and [[pexidartinib]] (Turalio) are two FDA approved drugs developed by Plexxikon
*[[Vemurafenib]] (Zelboraf) and [[pexidartinib]] (Turalio) are two FDA approved drugs developed by Plexxikon


*Plexxikon is collaborating with [[Wyeth Pharmaceuticals]] on several products for use in type II diabetes and other metabolic disorders.<ref>{{Cite web|last=|first=|date=28 October 2004|title=Wyeth, Plexxikon tie up to develop novel diabetes & metabolic disorders treatment|url=http://www.pharmabiz.com/article/detnews.asp?SecArch=&articleid=24409&sectionid=14|url-status=dead|archive-url=https://web.archive.org/web/20071024140445/http://www.pharmabiz.com/article/detnews.asp?SecArch=&articleid=24409&sectionid=14|archive-date=24 October 2007|access-date=|website=}}</ref> The most advanced of these agents is indeglitazar (PLX204), which is currently in Phase II clinical trials for [[type 2 diabetes]].<ref>{{Cite web|last=|first=|date=|title=Study Evaluating PPM-204 In Subjects With Type 2 Diabetes - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT00425919|url-status=live|archive-url=|archive-date=|access-date=2020-10-09|website=Clinical Trials|language=en}}</ref>
*Plexxikon is collaborating with [[Wyeth Pharmaceuticals]] on several products for use in type II diabetes and other metabolic disorders.<ref>{{Cite web|last=|first=|date=28 October 2004|title=Wyeth, Plexxikon tie up to develop novel diabetes & metabolic disorders treatment|url=http://www.pharmabiz.com/article/detnews.asp?SecArch=&articleid=24409&sectionid=14|url-status=dead|archive-url=https://web.archive.org/web/20071024140445/http://www.pharmabiz.com/article/detnews.asp?SecArch=&articleid=24409&sectionid=14|archive-date=24 October 2007|access-date=|website=}}</ref> The most advanced of these agents is indeglitazar (PLX204), which is currently in Phase II clinical trials for [[type 2 diabetes]].<ref>{{Cite journal|last=|first=|date=18 December 2007|title=Study Evaluating PPM-204 In Subjects With Type 2 Diabetes - Full Text View - ClinicalTrials.gov|url=https://clinicaltrials.gov/ct2/show/NCT00425919|archive-url=|archive-date=|access-date=2020-10-09|website=Clinical Trials|language=en}}</ref>


*PLX7486 is a [[CSF1R]] antagonist and pan-TRK inhibitor in clinical trials for advanced solid tumors.<ref>{{Cite web | url = https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fms-trk-tyrosine-kinase-inhibitor-plx7486 | title = Fms/Trk tyrosine kinase inhibitor PLX7486 | work = NCI Drug Dictionary | publisher = National Cancer Institute }}</ref><ref>{{Cite web|last=|first=|date=|title=Phast 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors|url=https://clinicaltrials.gov/ct2/show/NCT01804530|url-status=live|archive-url=|archive-date=|access-date=|website=}}</ref>
*PLX7486 is a [[CSF1R]] antagonist and pan-TRK inhibitor in clinical trials for advanced solid tumors.<ref>{{Cite web | url = https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fms-trk-tyrosine-kinase-inhibitor-plx7486 | title = Fms/Trk tyrosine kinase inhibitor PLX7486 | work = NCI Drug Dictionary | publisher = National Cancer Institute }}</ref><ref>{{Cite journal|date=2018-08-02|title=Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors|url=https://clinicaltrials.gov/ct2/show/NCT01804530|url-status=live|archive-url=https://web.archive.org/web/20211117224901/https://clinicaltrials.gov/ct2/show/NCT01804530|archive-date=2021-11-17|website=ClinicalTrials.gov}}</ref>


==References==
==References==

Latest revision as of 08:20, 9 May 2024

Plexxikon
Company typeSubsidiary
IndustryBiotechnology
Founded2001 (2001)
FounderJoseph Schlessinger
Defunct2011; 13 years ago (2011)
FateAcquired by the Daiichi Sankyo
HeadquartersSouth San Francisco, California, United States.
Websitewww.plexxikon.com Edit this on Wikidata

Plexxikon is an American drug discovery company based in South San Francisco, California. It was co-founded in 2001 by Joseph Schlessinger of Yale University, and Sung-Hou Kim of the University of California, Berkeley.

It uses a proprietary structural biology-based platform called Scaffold-Based Drug Discovery to build a pipeline of products in multiple therapeutic areas. This discovery process integrates multiple technologies, including structural screening as one key component, that it hopes will give a significant competitive advantage over other approaches.[citation needed][1]

In April 2011, Plexxikon was acquired by the Japanese pharmaceutical company Daiichi Sankyo for $805 million and an additional $130 million in potential milestone payments.[2][3][4]

Daiichi Sankyo announced the shutdown of Plexxikon in 2022.[5]

Drug pipeline[edit]

  • Plexxikon is collaborating with Wyeth Pharmaceuticals on several products for use in type II diabetes and other metabolic disorders.[6] The most advanced of these agents is indeglitazar (PLX204), which is currently in Phase II clinical trials for type 2 diabetes.[7]
  • PLX7486 is a CSF1R antagonist and pan-TRK inhibitor in clinical trials for advanced solid tumors.[8][9]

References[edit]

  1. ^ "AI Drug Discovery: Key Trends and Developments in Pharmaceutical Industry". www.biopharmatrend.com. Retrieved 2023-09-11.
  2. ^ "Daiichi Sankyo to Acquire Plexxikon". Plexxikon. 2011-02-28. Archived from the original on 2011-03-06.
  3. ^ "Plexxikon acquired by Daiichi Sankyo". Haberman Associates. 2011-03-03. Retrieved 2020-08-06.
  4. ^ "Daiichi Sankyo, Inc. Completes Plexxikon Inc. Acquisition". BioSpace. Retrieved 2020-08-06.
  5. ^ Wells, Madeline (2022-01-12). "South SF company bought for $800 million is being shut down". SFGATE. Archived from the original on 2022-01-12.
  6. ^ "Wyeth, Plexxikon tie up to develop novel diabetes & metabolic disorders treatment". 28 October 2004. Archived from the original on 24 October 2007.
  7. ^ "Study Evaluating PPM-204 In Subjects With Type 2 Diabetes - Full Text View - ClinicalTrials.gov". Clinical Trials. 18 December 2007. Retrieved 2020-10-09.
  8. ^ "Fms/Trk tyrosine kinase inhibitor PLX7486". NCI Drug Dictionary. National Cancer Institute.
  9. ^ "Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors". ClinicalTrials.gov. 2018-08-02. Archived from the original on 2021-11-17.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Plexxikon&oldid=1223005233"